Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. - Wikidata - awgldk - TriplyDB

Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection.

Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection.

http://www.wikidata.org/entity/Q34653838

about

TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease Tumour necrosis factor-mediated macrophage activation in the target organ is critical for clinical manifestation of uveitis TNF biology, pathogenic mechanisms and emerging therapeutic strategies Cyclooxygenase-2 or tumor necrosis factor-α inhibitors attenuate the mechanotransductive effects of pulsed focused ultrasound to suppress mesenchymal stromal cell homing to healthy and dystrophic muscle AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease Inhibition of soluble tumor necrosis factor ameliorates synaptic alterations and Ca2+ dysregulation in aged rats Differential expression and tumor necrosis factor-mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas.Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia.Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia Hippocampal TNFα Signaling Contributes to Seizure Generation in an Infection-Induced Mouse Model of Limbic Epilepsy.Dendritic-cell exosomes cross-present Toll-like receptor-ligands and activate bystander dendritic cells.A crucial role for tumor necrosis factor receptor 1 in synovial lining cells and the reticuloendothelial system in mediating experimental arthritis Reactivation of M. tuberculosis infection in trans-membrane tumour necrosis factor mice.Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology.Central but not systemic administration of XPro1595 is therapeutic following moderate spinal cord injury in mice Antagonistic TNF receptor one-specific antibody (ATROSAB): receptor binding and in vitro bioactivity Tumor necrosis factor-neuropeptide Y cross talk regulates inflammation, epithelial barrier functions, and colonic motility.ADAM17-mediated processing of TNF-α expressed by antiviral effector CD8+ T cells is required for severe T-cell-mediated lung injury.zVAD-induced necroptosis in L929 cells depends on autocrine production of TNFα mediated by the PKC-MAPKs-AP-1 pathway.Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination Brazilin isolated from Caesalpinia sappan L. inhibits rheumatoid arthritis activity in a type-II collagen induced arthritis mouse model The immunological contribution to heterotopic ossification disorders.Pharmacokinetic and Pharmacodynamic Characterisation of an Anti-Mouse TNF Receptor 1 Domain Antibody Formatted for In Vivo Half-Life Extension.Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15.Etanercept treatment enhances clinical and neuroelectrophysiological recovery in partial spinal cord injury Neuroinflammation in glaucoma: soluble tumor necrosis factor alpha and the connection with excitotoxic damage.Transmembrane TNF-TNFR2 Impairs Th17 Differentiation by Promoting Il2 Expression.B-lymphopoiesis is stopped by mobilizing doses of G-CSF and is rescued by overexpression of the anti-apoptotic protein Bcl2 Peripheral elevation of TNF-α leads to early synaptic abnormalities in the mouse somatosensory cortex in experimental autoimmune encephalomyelitis Ankylosing spondylitis: from cells to genes Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats Remission of severe aphthous stomatitis of celiac disease with etanercept.Selective effects of a therapeutic protein targeting tumor necrosis factor-alpha on cytochrome P450 regulation during infectious colitis: Implications for disease-dependent drug-drug interactions.Antagonists of TNF action: clinical experience and new developments.Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease?Cytokines and mucosal immunity.Leukocyte production of inflammatory mediators is inhibited by the antioxidants phloretin, silymarin, hesperetin, and resveratrol.Tumor necrosis factor suppresses NR5A2 activity and intestinal glucocorticoid synthesis to sustain chronic colitis.Hepatocellular carcinoma repression by TNFα-mediated synergistic lethal effect of mitosis defect-induced senescence and cell death sensitization.sCD48 is anti-inflammatory in Staphylococcus aureus Enterotoxin B-induced eosinophilic inflammation.

P2860

Q21093232-810D1F6E-0200-4A19-86E6-112A3B123E83 Q24633598-75E9495D-9E86-46DB-9243-01CD1B2DB936 Q26776492-CFA41304-B98B-4FE1-928C-F48E0E9D667A Q27329655-9797D76A-BA51-4177-B66F-B81B50EFBEFC Q27334472-64AE13E0-13BE-4F0E-93FF-D784DC61DAC1 Q28577238-632AAA6F-BAFE-4CC2-BA31-9ACF7D832B07 Q30412235-5205273A-CC3F-4CD5-8E7D-B928B7D75660 Q30610169-986F56A0-12FC-441D-8FDE-903229F47775 Q33578973-A538A375-CFFE-4CB1-8E39-4105268B984D Q33651396-71A9675F-7E84-4E21-B143-E4E2FF5650F7 Q33709414-04A5A21A-6B50-45BE-861D-FCA0FC71E691 Q33923409-9B4E3BED-3649-4DB1-8569-8A847CB9CF59 Q34087566-77CE1ACE-6021-4A86-8EAD-18B40BD94BAC Q34169743-C624305B-721B-46AA-BF3B-39E5FDBC61ED Q34250544-C20AB694-E10E-4201-81C3-F8864FA13048 Q34973492-C52D072B-4C0D-4D44-839D-D6142E819758 Q35012750-A3113987-CC51-40A0-AA5F-9D3F3A3EA197 Q35040269-52E2303C-FCB9-40F3-BFA1-707C95234E84 Q35092587-ABBB8FEB-35C2-4E57-9ED3-87558B711FF5 Q35206971-14DCFABA-A0B3-4A4E-A6C7-74113508A526 Q35540738-F76DB1EA-D679-45AA-9D8C-D9D05F80460C Q35563973-FD9A0B67-6ED7-4CEA-A47E-721B4C531FE0 Q35768046-EB286EF4-F4B1-4824-A056-CC9DE0B77EFF Q35883106-93EBBC46-33E0-4449-B458-324B96F40C9E Q36428524-E389BD2F-3CCD-4A17-9D79-7FF7D7FE38D4 Q36790827-AF281C0E-273A-4085-8425-CFEB9408E968 Q36826546-12B16DCE-9FFD-4072-B1BC-06D837C2FD1B Q36862313-182EBAEC-F8D7-4F68-A12B-57E542C23294 Q36950333-7B716521-CFA9-462D-8963-C461E3C775AA Q37077734-0E084D20-A321-4E12-9D25-252B6ACC60E8 Q37162724-FA933266-2F4C-473A-8D92-6DE108ADF084 Q37425215-51BBCE3A-457F-4F70-8600-919E26570434 Q37679511-7BBEDFF6-D83B-43C0-AF62-0950C128C2FC Q38089191-174B618F-2AA7-47B2-ADBE-795A22C26F34 Q38103856-49D51A48-183A-4971-846D-5D7931D1D2C3 Q38247384-E6EFC68B-2D3B-4379-9AFE-74C88BBF7A2B Q38269769-DFDB053A-A008-44CF-9C69-87D9040250F0 Q39020790-0B9ADC7D-409C-4970-AA23-3E314103CCE1 Q39767815-9723E13D-A2C6-4FD6-9A64-E72EA7C66EE7 Q40032051-570A0327-AAB1-4D33-A546-0DFBC49C56A1

P2860

Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection.

http://www.wikidata.org/entity/Q34653838

description

2007 nî lūn-bûn

@nan

2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Dominant-negative inhibitors o ...... innate immunity to infection.

@ast

Dominant-negative inhibitors o ...... innate immunity to infection.

@en

Dominant-negative inhibitors o ...... innate immunity to infection.

@nl

type

label

Dominant-negative inhibitors o ...... innate immunity to infection.

@ast

Dominant-negative inhibitors o ...... innate immunity to infection.

@en

Dominant-negative inhibitors o ...... innate immunity to infection.

@nl

prefLabel

Dominant-negative inhibitors o ...... innate immunity to infection.

@ast

Dominant-negative inhibitors o ...... innate immunity to infection.

@en

Dominant-negative inhibitors o ...... innate immunity to infection.

@nl

P1433

Q34653838-3CDBA8C6-9709-4576-A6C3-B5D6C185111C

P1476

Q34653838-86A58E06-1DBA-4BBB-9ABA-489FD4E2AADE

P2093

Q34653838-21BFD566-F7C1-4E00-92D6-D5041AD8F767

Q34653838-2402C2C0-6453-4AA0-9E89-CD28B4B0C254

Q34653838-2A45E669-4F63-4C76-A407-D79AEBBB2181

Q34653838-3650CABA-F158-4337-A8CC-D916B0C5DAEF

Q34653838-3B8D3ADB-D7A7-4963-A1DF-7B3B3126813A

Q34653838-3CF7062C-8699-45D0-8060-D6003292C67B

Q34653838-3E61FB9A-C584-4884-B2D1-935662FBBBAA

Q34653838-9AEFD3FA-3339-4464-8123-70BF1284E8DA

Q34653838-9C85DFFD-2D27-45C3-A1EC-D38BFE540DE6

Q34653838-C974B3B5-B061-465C-9964-B639F2055BD3

P304

Q34653838-FF350092-C6DD-4419-8552-F5923E9E4673

P31

Q34653838-83486884-5111-417F-A25A-CFC44E6BAD58

P356

Q34653838-B1F8DB84-D8E6-4BBC-B893-5BAABF93F0B6

P407

Q34653838-2EA6DBE7-8256-4E9F-874B-22052021A193

P433

Q34653838-1735E2E3-5BAC-45EF-BABF-B2DC5E8DAACD

P478

Q34653838-F9440F8F-1236-4924-B14A-27CDD43B5314

P50

Q34653838-4127271F-9EB8-4DBD-966A-CA67BEE0F954

P577

Q34653838-2D6000E3-E969-4D40-B421-55DD1CC78339

P5875

Q34653838-2CA876DF-3BD8-4C16-B62C-5921E0A43DC7

P698

Q34653838-9D2241FF-91AF-4730-8170-9D0536287DEB

P921

Q34653838-47A074C7-5249-42CD-AE3E-9EDD8F02051F

P356

JIMMUNOL.179.3.1872

P1433

Journal of Immunology

P1476

Dominant-negative inhibitors o ...... innate immunity to infection.

@en

P2093

Araz Eivazi

http://www.w3.org/2001/XMLSchema#string

Christopher O'Brien

http://www.w3.org/2001/XMLSchema#string

David E Szymkowski

http://www.w3.org/2001/XMLSchema#string

Duc-Hanh T Nguyen

http://www.w3.org/2001/XMLSchema#string

François Erard

http://www.w3.org/2001/XMLSchema#string

James Kung

http://www.w3.org/2001/XMLSchema#string

Jonathan Zalevsky

http://www.w3.org/2001/XMLSchema#string

Laure Janot

http://www.w3.org/2001/XMLSchema#string

Paul M Steed

http://www.w3.org/2001/XMLSchema#string

Sergei A Ezhevsky

http://www.w3.org/2001/XMLSchema#string

P304

1872-1883

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.179.3.1872

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

179

http://www.w3.org/2001/XMLSchema#string

P50

Bernhard Ryffel

P577

2007-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6197685

http://www.w3.org/2001/XMLSchema#string

P698

17641054

http://www.w3.org/2001/XMLSchema#string

P921